When was Fractyl founded?

Fractyl was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Fractyl located?

Fractyl is headquartered in Lexington, United States.

How many employees does Fractyl have?

As of Sep 30, 2026, the latest employee count at Fractyl is 105.

Is Fractyl a funded company?

Fractyl is a funded company, having raised a total of $345M across 7 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 21, 2013.

When was the latest funding round of Fractyl?

Fractyl's latest funding was a $***** Series F round on Jun 16, 2021, with participation from 3 investors.

What is the annual revenue of Fractyl?

Annual revenue of Fractyl is less than $1M as on Dec 31, 2024

Where does Fractyl rank among its competitors?

Fractyl ranks 11th amongst 57 active competitors, of which 24 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Congruence Therapeutics, which secured $39.5M in Mar, 2026.

Who are the top competitors of Fractyl?

Fractyl's top competitors include Adocia, MeiraGTx and D&D Pharmatech. Among them, Congruence Therapeutics secured the most recent funding round in March, 2026.

Fractyl - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Provider of Endoscopic procedure for type - 2 diabetes. Fractyl is developing an investigational, device-based, minimally invasive, trans-oral procedure known as Revita duodenal mucosal resurfacing (DMR) that aims to improve the body's response to sugar. Performed using Fractyl’s proprietary Revita System, the DMR procedure uses hydrothermal ablation to modify the lining of the duodenum. Fractyl’s proprietary Revita™ System consists of a console and a novel single-use balloon catheter. The physician first introduces the Revita™ catheter through the mouth into the small intestine using a standard endoscope to visualize the catheter position. The physician then uses the Revita™ System to activate a precisely controlled heated balloon at the end of the catheter to treat the lining of the duodenum. The lining of the duodenum contains cells that affect glucose control and insulin resistance.

Website: fractyl.com
Social
Email ID: *****@fractyl.com

Key Metrics

Founded Year

2010

Location

Lexington, United States

Stage

Public

Total Funding

$345M in 7 rounds

Latest Funding Round

Series F, Jun 16, 2021, $*****

Investors

Deerfield Triarc Capital & 18 more

Ranked

11^th among 57 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

105 as on Sep 30, 2026

Similar Companies

Adocia & 61 more

Exit Details

Public

View Fractyl's full profile

Fractyl is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Fractyl Health, Inc. CIN: 1572616 , United States, Active		$0 - $1M (As on Dec 31, 2024)	-	-
Fractyl Health, Inc CIN: 1572616 , United States, Active	Jul 15, 2019	-	102 (As on Dec 31, 2024)	-
Fractyl Laboratories, Inc. CIN: 27-3553477 , United States, Active		-	-	-

Fractyl got listed on Feb 02, 2024.

Click here to take a look at Fractyl's IPO in detail

Fractyl has raised a total funding of $345M over 7 rounds. Its first funding round was on Mar 21, 2013. Its latest funding round was a Series F round on Jun 16, 2021 for $*****. 3 investors participated in its latest round. Fractyl has 19 institutional investors.

Here is the list of recent funding rounds of Fractyl:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 16, 2021	7741381	Series F	6993672	1300430	6262757	8836270
Aug 06, 2020	7348722	Series E	3935330	8124352	3653520	Bessemer Venture Partners & 9 more
Mar 19, 2020	5157396	Series D	1675445	5000177	5031568	8746545

Access funding benchmarks and valuations. Sign up today!

View details of Fractyl's funding rounds and investors

The founders of Fractyl is Harith Rajagopalan.

Here are the details of Fractyl's key team members:

Harith Rajagopalan: Co-founder and President of Fractyl.

View details of Fractyl's Founder profiles and Board Members

Fractyl's employee count trend

Fractyl has 105 employees as of Sep 26. Here is Fractyl's employee count trend over the years:

Uncover Fractyl's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Fractyl include Adocia, MeiraGTx and D&D Pharmatech. Here is the list of Top 10 competitors of Fractyl, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
2nd	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Orbimed & 6 others	65/100
3rd	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
4th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
5th	MBX Biosciences 2018, Carmel (United States), Public	Developer of drugs for the treatment of rare endocrine diseases	$216M	Deep Track Capital, Wellington & 9 others	61/100
6th	Metsera 2022, New York City (United States), Acquired	Biopharmaceutical company focusing on medicines for obesity and metabolic diseases	$505M	Wellington, Arch Venture Partners & 16 others	61/100
7th	Congruence Therapeutics 2021, Montreal (Canada), Series B	Developer of therapeutics for the treatment of rare diseases	$136M	Amplitude, Orbimed & 9 others	61/100
8th	Skye Bioscience 2011, San Diego (United States), Public	Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases	$1.97M	Hilco Vision, Ally Bridge Group & 6 others	57/100
9th	Biophytis 2006, Romainville (France), Public	Developer of drugs for neuromuscular and age-related diseases	$2.6M	Kreos Capital, Seventure Partners & 1 others	56/100
10th	Remedy Plan 2011, Washington, DC (United States), Series B	Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases	$24.7M	Alexandria, Schooner Capital	56/100
11th	Fractyl 2010, Lexington (United States), Public	Provider of Endoscopic procedure for type - 2 diabetes	$345M	Mithril, Maverick Ventures & 17 others	56/100